In the future, the use of NEDA-4 status or of new biomarkers (Disanto et al., 2017; Beadnall et al., 2019), like serum neurofilament light chains (sNfL), may be seen as additional tools to be integrated into the clinical equation of the follow-up of children and adolescents with MS. The gene discussed is NEFL; the disease is myeloid sarcoma.